Standard of Care in the Era of PrEP

November 22, 2017
Every research trial of a new HIV prevention option offers a package of services to protect participants from HIV. This standard of care is essential to the design of an ethical trial.

So what do we do now that Oral PrEP has hit the world: It works if you take it; roll out is reaching some places and populations better than others. And people on PrEP often need support to stick with it. All this makes adding Oral PrEP a paramount question for trials. This month’s Px Pulse follows a recent summit in Cape Town South Africa where advocates, researchers and regulators confronted the high stakes of post-PrEP prevention research.

Listen to the full podcast (18:07)

Highlights

• Tian Johnson: An advocates perspective on Standard of Care (00:54)
• Tian Johnson queries Sinead Delany-Moretlwe on PrEP at Trials (01:52)
• On the Implications for Trial Design: Big, Complex, Expensive? (01:58)
• Looking ahead: Will PrEP at Trial Sites Expand Prevention Services (02:09)
• Yvette Raphael Talks about the Role of Advocates on Trial Design and Standard of Care (07:13)

Additional Resources

• Vaccine Advocacy Resource Group (VARG) Imbizo Statement
• HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials
• Webinar: HIV Research in the Era of PrEP: The implications of TDF/FTC for biomedical prevention trials

More Px Pulse

For more episodes of Px Pulse, click here.